TY - JOUR
T1 - A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
AU - Aksman, Leon M.
AU - Oxtoby, Neil P.
AU - Scelsi, Marzia A.
AU - Wijeratne, Peter A.
AU - Young, Alexandra L.
AU - Alves, Isadora Lopes
AU - Collij, Lyduine E.
AU - ADNI
AU - Vogel, Jacob W.
AU - Barkhof, Frederik
AU - Alexander, Daniel C.
AU - Altmann, Andre
N1 - Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 666992 (L.M.A., N.P.O. and D.C.A). L.M.A. was partially supported by the National Institute Of Biomedical Imaging And Bioengineering of the National Institutes of Health under Award Number P41EB015922 and by the National Institute On Aging of the National Institutes of Health under Award Number P30AG066530. N.P.O. is a UKRI Future Leaders Fellow (MRC MR/S03546X/1). This project was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. P.A.W. was funded by a Medical Research Council Skills Development Fellowship (MR/T027770/1). A.L.Y. is supported by an MRC Skills Development Fellowship (MR/T027800/1). EPSRC grant EP/M020533/1 also supports this work. A.A. holds a Medical Research Council eMedLab Medical Bioinformatics Career Development Fellowship. This work was supported by the Medical Research Council (grant number MR/L016311/1: E-DADS). This work has received support from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (AMYPAD, grant No 115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. L.E.C. has received research support by GE Healthcare (paid to institution). Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 666992 (L.M.A., N.P.O. and D.C.A). L.M.A. was partially supported by the National Institute Of Biomedical Imaging And Bioengineering of the National Institutes of Health under Award Number P41EB015922 and by the National Institute On Aging of the National Institutes of Health under Award Number P30AG066530. N.P.O. is a UKRI Future Leaders Fellow (MRC MR/S03546X/1). This project was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. P.A.W. was funded by a Medical Research Council Skills Development Fellowship (MR/T027770/1). A.L.Y. is supported by an MRC Skills Development Fellowship (MR/T027800/1). EPSRC grant EP/M020533/1 also supports this work. A.A. holds a Medical Research Council eMedLab Medical Bioinformatics Career Development Fellowship. This work was supported by the Medical Research Council (grant number MR/L016311/1: E-DADS). This work has received support from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (AMYPAD, grant No 115952). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. L.E.C. has received research support by GE Healthcare (paid to institution). Funding Information: Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Publisher Copyright: © 2023 The Author(s). Published by Oxford University Press on behalf of the Guarantors of Brain.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Amyloid-β is thought to facilitate the spread of tau throughout the neocortex in Alzheimer's disease, though how this occurs is not well understood. This is because of the spatial discordance between amyloid-β, which accumulates in the neocortex, and tau, which accumulates in the medial temporal lobe during ageing. There is evidence that in some cases amyloid-β-independent tau spreads beyond the medial temporal lobe where it may interact with neocortical amyloid-β. This suggests that there may be multiple distinct spatiotemporal subtypes of Alzheimer's-related protein aggregation, with potentially different demographic and genetic risk profiles. We investigated this hypothesis, applying data-driven disease progression subtyping models to post-mortem neuropathology and in vivo PET-based measures from two large observational studies: the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Religious Orders Study and Rush Memory and Aging Project (ROSMAP). We consistently identified 'amyloid-first' and 'tau-first' subtypes using cross-sectional information from both studies. In the amyloid-first subtype, extensive neocortical amyloid-β precedes the spread of tau beyond the medial temporal lobe, while in the tau-first subtype, mild tau accumulates in medial temporal and neocortical areas prior to interacting with amyloid-β. As expected, we found a higher prevalence of the amyloid-first subtype among apolipoprotein E (APOE) ε4 allele carriers while the tau-first subtype was more common among APOE ε4 non-carriers. Within tau-first APOE ε4 carriers, we found an increased rate of amyloid-β accumulation (via longitudinal amyloid PET), suggesting that this rare group may belong within the Alzheimer's disease continuum. We also found that tau-first APOE ε4 carriers had several fewer years of education than other groups, suggesting a role for modifiable risk factors in facilitating amyloid-β-independent tau. Tau-first APOE ε4 non-carriers, in contrast, recapitulated many of the features of primary age-related tauopathy. The rate of longitudinal amyloid-β and tau accumulation (both measured via PET) within this group did not differ from normal ageing, supporting the distinction of primary age-related tauopathy from Alzheimer's disease. We also found reduced longitudinal subtype consistency within tau-first APOE ε4 non-carriers, suggesting additional heterogeneity within this group. Our findings support the idea that amyloid-β and tau may begin as independent processes in spatially disconnected regions, with widespread neocortical tau resulting from the local interaction of amyloid-β and tau. The site of this interaction may be subtype-dependent: medial temporal lobe in amyloid-first, neocortex in tau-first. These insights into the dynamics of amyloid-β and tau may inform research and clinical trials that target these pathologies.
AB - Amyloid-β is thought to facilitate the spread of tau throughout the neocortex in Alzheimer's disease, though how this occurs is not well understood. This is because of the spatial discordance between amyloid-β, which accumulates in the neocortex, and tau, which accumulates in the medial temporal lobe during ageing. There is evidence that in some cases amyloid-β-independent tau spreads beyond the medial temporal lobe where it may interact with neocortical amyloid-β. This suggests that there may be multiple distinct spatiotemporal subtypes of Alzheimer's-related protein aggregation, with potentially different demographic and genetic risk profiles. We investigated this hypothesis, applying data-driven disease progression subtyping models to post-mortem neuropathology and in vivo PET-based measures from two large observational studies: the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Religious Orders Study and Rush Memory and Aging Project (ROSMAP). We consistently identified 'amyloid-first' and 'tau-first' subtypes using cross-sectional information from both studies. In the amyloid-first subtype, extensive neocortical amyloid-β precedes the spread of tau beyond the medial temporal lobe, while in the tau-first subtype, mild tau accumulates in medial temporal and neocortical areas prior to interacting with amyloid-β. As expected, we found a higher prevalence of the amyloid-first subtype among apolipoprotein E (APOE) ε4 allele carriers while the tau-first subtype was more common among APOE ε4 non-carriers. Within tau-first APOE ε4 carriers, we found an increased rate of amyloid-β accumulation (via longitudinal amyloid PET), suggesting that this rare group may belong within the Alzheimer's disease continuum. We also found that tau-first APOE ε4 carriers had several fewer years of education than other groups, suggesting a role for modifiable risk factors in facilitating amyloid-β-independent tau. Tau-first APOE ε4 non-carriers, in contrast, recapitulated many of the features of primary age-related tauopathy. The rate of longitudinal amyloid-β and tau accumulation (both measured via PET) within this group did not differ from normal ageing, supporting the distinction of primary age-related tauopathy from Alzheimer's disease. We also found reduced longitudinal subtype consistency within tau-first APOE ε4 non-carriers, suggesting additional heterogeneity within this group. Our findings support the idea that amyloid-β and tau may begin as independent processes in spatially disconnected regions, with widespread neocortical tau resulting from the local interaction of amyloid-β and tau. The site of this interaction may be subtype-dependent: medial temporal lobe in amyloid-first, neocortex in tau-first. These insights into the dynamics of amyloid-β and tau may inform research and clinical trials that target these pathologies.
KW - Alzheimer's disease
KW - PART
KW - PET imaging
KW - data-driven subtyping
KW - neuropathology
UR - http://www.scopus.com/inward/record.url?scp=85178650888&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/brain/awad232
DO - https://doi.org/10.1093/brain/awad232
M3 - Article
C2 - 37433038
SN - 0006-8950
VL - 146
SP - 4935
EP - 4948
JO - Brain
JF - Brain
IS - 12
ER -